In schizophrenia, comparing treatment dropouts between olanzapine and risperidone can be useful to better understand their relative effectiveness.
OBJECTIVE:
To analyze the differences in the rates of dropout from clinical trials and response between these 2 antipsychotics.
METHODS:
Literature search was based on MEDLINE (1966–May 2002). Analysis 1 included 4 randomized studies (838 patients), analysis 2 included 2 randomized studies (n = 716), and analysis 3 assessed 5 clinical studies for olanzapine (n = 928) and 3 for risperidone (n = 290). Odds ratios were estimated by the fixed-effect model.
RESULTS:
The risk of treatment discontinuation (analysis 1) was significantly greater for risperidone than for olanzapine (42% vs. 33%, respectively). The response rates were identical for the 2 drugs (analysis 2). A slightly better pattern of maintenance of response was found for olanzapine (analysis 3).
CONCLUSIONS:
The pattern of dropout and maintenance of remission seems to be better controlled for olanzapine than for risperidone.
AndersonIMTomensonBM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: an analysis. BMJ1995; 310: 1433–8.
2.
BrodieMJOverstallPWGiorgiL.Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res1999; 37: 81–7.
3.
ChadwickD.Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet1999; 354: 13–9.
4.
EmeryPZeidlerHKvienTKGuslandiMNaudinRSteadH, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet1999; 354: 2106–11.
5.
Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology1995; 45: 1277–85.
6.
HamiltonSHEdgellETRevickiDABreierA.Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol2000; 15: 245–55.
7.
Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group. Epilepsia1999; 40: 1767–74.
8.
PolSCouzigouPBourliereMAbergelACombisJMLarreyD, et al. Randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. J Hepatol1999; 31: 1–7.
9.
PopeJEBellamyNSeiboldJRBaronMEllmanMCaretteS, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum2001; 44: 1351–8.
10.
SamuelianJCHackettDA. Randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression. J Psychopharmacol1998; 12: 273–8.
11.
SeesKLDelucchiKLMassonCRosenAClarkHWRobillardH, et al. Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA2000; 283: 1303–10.
12.
WalkerMCLiLMSanderJW. Long-term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome. BMJ1996; 313: 1184–5.
13.
MarsonAGKadirZAChadwickDW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ1996; 313: 1169–74.
14.
RosenheckRCramerJXuWThomasJHendersonWFrismanL, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med1997; 337: 809–15.
15.
MessoriATrippoliSVaianiMGoriniMCorradoA.Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: analysis of randomised controlled trials. BMJ2000; 321: 1103–6.
16.
MessoriATrippoliSVaianiMCattelF.Survival analysis of individual patient data and survival analysis of published (aggregate) data. Clin Drug Invest2000; 20: 309–16.
17.
LauJAntmanEMJimenez-SilvaJKupelnickBMostellerFChalmersTC. Cumulative analysis of therapeutic trials for myocardial infarction. N Engl J Med1992; 327: 248–54.
18.
FineHADearKBLoefflerJSBlackPMCanellosGP. Analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer1993; 71: 2585–92.
19.
TralloriGMessoriAScuffiCBardazziGSilvanoRd'AlbasioG, et al. Effectiveness of 5-aminosalicylic acid enemas for maintaining remission in patients with left-sided ulcerative colitis: a meta-and economic analysis. J Clin Gastroenterol1995; 20: 257–9.
20.
MessoriABrignolaCTralloriGRampazzoRBardazziGBelloliC, et al. Effectiveness of 5-aminosalicylic acid (5-ASA) for maintaining remission in patients with Crohn's disease: an analysis. Am J Gastroenterol1994; 89: 692–8.
21.
BardelliFMessoriARampazzoRAlbertiAMartiniN.Effect of recombinant or lymphoblastoid alpha interferon on ALT in patients with chronic hepatitis C or chronic non-A non-B hepatitis: an analysis. Clin Drug Invest1995; 9: 239–54.
22.
FerrandinaGScambiaGBardelliFPaniciP BenedettiMancusoSMessoriA.Relationship between cathepsin-D content and disease-free dropout rate in node-negative breast cancer patients: an analysis. Br J Cancer1997; 76: 661–6.
23.
MessoriABosiABacciSLaszloDTrippoliSLocatelliF, et al. Retrospective dropout rate analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Bone Marrow Transplant1999; 23: 489–95.
24.
MessoriATrippoliSBecagliPZaccaraG.Cost-effectiveness of riluzole in amyotrophic lateral sclerosis. Pharmacoeconomics1999; 16: 153–63.
25.
MessoriAVaianiMTrippoliSRigacciLJerkemanMLongoG.Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer2001; 84: 303–7.
26.
CollinsRYusufSPetoR.Overview of randomised trials of diuretics in pregnancy. BMJ1985; 290: 17–23.
27.
TollefsonGDAndersenSWTranPV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry1999; 46: 365–73.
28.
TranPVHamiltonSHKuntzAJPotvinJHAndersenSWBeasleyCJr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol1997; 17: 407–18.
29.
PurdonSEJonesBDStipELabelleAAddingtonDDavidSR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry2000; 57: 249–58.
30.
ConleyRRMahmoudR.A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry2001; 158: 765–74.
31.
VolavkaJCzoborPSheitmanBLindenmayerJPCitromeLMcEvoyJP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry2002; 159: 255–60.
32.
TranPVDellvaMATollefsonGDBeasleyCMJrPotvinJHKieslerG.Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry1997; 58: 205–11.
33.
TranPVDellvaMATollefsonGDWentleyALBeasleyCM. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry1998; 172: 499–505.
34.
DellvaMATranPTollefsonGDWentleyALBeasleyCMJr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv1997; 48: 1571–7.
35.
TollefsonGDBeasleyCMJrTranPVStreetJSKruegerJATamuraRN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry1997; 154: 457–65.
36.
MallaAKNormanRMScholtenDJZirulSKottedaV.A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry2001; 62: 179–84.
37.
CsernanskyJGMahmoudRBrennerR.A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. The Risperidone-USA-79 Study Group. N Engl J Med2002; 346: 16–22.
38.
GeddesJFreemantleNHarrisonPBebbingtonP.Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ2000; 321: 1371–6.
39.
AdamsCDugganL.Atypical antipsychotics in the treatment of schizophrenia. Paper corrupts concept of evidence based medicine. BMJ2001; 322: 927–8.
40.
WetterlingT.Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf2001; 24: 59–73.
41.
KoroCEFedderDOL'ItalienGJWeissSSMagderLSKreyenbuhlJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case–control study. BMJ2002; 325: 243.
